Opendata, web and dolomites

Trep-AB SIGNED

Repurposing clinically approved antibacterial drugs for treponematoses therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Trep-AB project word cloud

Explore the words cloud of the Trep-AB project. It provides you a very rough idea of what is the project "Trep-AB" about.

culture    antibiotic    candidate    clarify    broadly    combination    treatment    drugs    risk    mutations    efficacy    bacteria    stages    penicillin    jeopardize    unknown    global    campaign    drug    regimens    similarity    good    infection    strains    acquire    validated    speaking    central    lesion    options    macrolide    treponema    human    survive    patients    resistant    treponematoses    biological    reduce    injectable    experimentally    shows    yaws    investigational    current    cns    trials    standard    randomized    advantage    profile    pallidum    tremendous    conducting    basis    expertise    allergy    computational    antibiotics    cure    candidates    resource    recurrent    restricted    clinical    treponemal    susceptibility    confirmed    prediction    team    penetration    burden    therapeutic    events    prioritized    spirochetes    syphilis    disseminate    azithromycin    confer    efficacious    lactams    nervous    microorganism    infected    resistance    eradication    antibacterial    shortage    grown    rabbits    preliminary    incorporate    oral   

Project "Trep-AB" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA 

Organization address
address: CARRETERA DE CANYET HOSPITAL GERMANS TRIAS I PUJOL PLANTA 2
city: BADALONA
postcode: 8916
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙498˙790 €
 EC max contribution 1˙498˙790 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2025-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA ES (BADALONA) coordinator 1˙150˙678.00
2    UNIVERSITY OF WASHINGTON US (SEATTLE WA) participant 348˙111.00

Map

 Project objective

Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a research program to have other validated treatment options with good CNS penetration that are efficacious for all the stages of treponemal infection. Our preliminary results using computational prediction of drug activity based on similarity to drugs with known activity against T.p. and other spirochetes shows several candidate antibiotics. I will take advantage of recent developments in culture methods for determination of drug susceptibility to test 20 prioritized drugs. These results will be confirmed in experimentally infected rabbits treated with the investigational drugs and assessed for lesion development and T.p. burden. My second approach will exploit the established expertise of my team conducting randomized clinical trials to evaluate the efficacy of the 2 most promising candidates compared to standard treatment to cure patients with syphilis/yaws. Such studies will incorporate in-depth studies of recurrent events among study participants, to further clarify the biological basis and identify mutations that confer resistance to B-lactams. New antibacterial oral drugs for the treatment of treponematoses will be a tremendous resource in case of penicillin treatment-failure, resistance, shortage, allergy, or for use in yaws combination regimens to reduce the likelihood of resistance selection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREP-AB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREP-AB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ERC VP CSA (2018)

Support to the Vice-Presidents of the ERC Scientific Council 2018

Read More  

CELPRED (2020)

Circuit elements of the cortical circuit for predictive processing

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More